Figure 6.
Figure 6. TNF-α levels. TNF-α levels in the sera of C3H/HeN LPS–sensitive (A) and C3H/HeJ LPS–resistant (B) mice. LPS and anti-CD61 nontreated control group (•), LPS-treatment alone group (○), anti-CD61–treated, LPS-treated group (□), anti-CD61–treated, LPS treated group with transfusion of 108 platelets from CD61-KO mice (▿), and anti-CD61–treated, LPS-treated group with a transfusion of 108 anti-CD61 F(ab′)2-masked platelets from C3H/HeJ mice (⋄) are shown. TNF-α levels were measured using a commercial ELISAkit. Arrows indicate treatment schedule times in the treated groups. Data are expressed as the mean ± SD concentration (pg/mL) of TNF-α in 5 mice per group.

TNF-α levels. TNF-α levels in the sera of C3H/HeN LPS–sensitive (A) and C3H/HeJ LPS–resistant (B) mice. LPS and anti-CD61 nontreated control group (•), LPS-treatment alone group (○), anti-CD61–treated, LPS-treated group (□), anti-CD61–treated, LPS treated group with transfusion of 108 platelets from CD61-KO mice (▿), and anti-CD61–treated, LPS-treated group with a transfusion of 108 anti-CD61 F(ab′)2-masked platelets from C3H/HeJ mice (⋄) are shown. TNF-α levels were measured using a commercial ELISAkit. Arrows indicate treatment schedule times in the treated groups. Data are expressed as the mean ± SD concentration (pg/mL) of TNF-α in 5 mice per group.

Close Modal

or Create an Account

Close Modal
Close Modal